About Genedit
Genedit is a company based in Berkeley (United States) founded in 2016.. Genedit has raised $93.5 million across 5 funding rounds from investors including Lilly, SK and Korea Investment Holdings. The company has 34 employees as of December 31, 2024. Genedit offers products and services including NanoGalaxy. Genedit operates in a competitive market with competitors including Ultragenyx, Alnylam, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
- Headquarter Berkeley, United States
- Employees 34 as on 31 Dec, 2024
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Genedit Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$93.5 M (USD)
in 5 rounds
-
Latest Funding Round
$35 M (USD), Series B
Nov 20, 2024
-
Investors
Lilly
& 14 more
-
Employee Count
34
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Genedit
Genedit offers a comprehensive portfolio of products and services, including NanoGalaxy. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables targeted delivery of genetic medicines for disease treatment.
Unlock access to complete
Unlock access to complete
Funding Insights of Genedit
Genedit has successfully raised a total of $93.5M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $35 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series B — $35.0M
-
First Round
First Round
(11 Dec 2018)
- Investors Count 15
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2024 | Amount | Series B - Genedit | Valuation | DSC Investment | |
| Jan, 2024 | Amount | Series A - Genedit | Valuation |
investors |
|
| Sep, 2021 | Amount | Series A - Genedit | Valuation | Lilly , Company K Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Genedit
Genedit has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, SK and Korea Investment Holdings. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage venture capital is invested primarily in South Korean startups.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Investment holding firm established in Seoul in 2003.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Genedit
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Genedit
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Genedit Comparisons
Competitors of Genedit
Genedit operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ultragenyx, Alnylam, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Developer of precision therapeutics for dry AMD and rare genetic diseases
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
AAV-based gene therapies for rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Genedit
Frequently Asked Questions about Genedit
When was Genedit founded?
Genedit was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Where is Genedit located?
Genedit is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Is Genedit a funded company?
Genedit is a funded company, having raised a total of $93.5M across 5 funding rounds to date. The company's 1st funding round was a Series A of $26M, raised on Dec 11, 2018.
How many employees does Genedit have?
As of Dec 31, 2024, the latest employee count at Genedit is 34.
What does Genedit do?
Genedit was founded in 2016 and is headquartered in Berkeley, United States. Operations focus on the biotechnology sector, where non-viral, non-lipid polymer nanoparticles are developed for drug delivery. The NanoGalaxy platform is employed to transport genetic medicines to specific tissues, enabling disease treatment. This approach supports targeted therapies in genetic medicine applications.
Who are the top competitors of Genedit?
Genedit's top competitors include Alnylam, BioMarin Pharmaceutical and Sirnaomics.
What products or services does Genedit offer?
Genedit offers NanoGalaxy.
Who are Genedit's investors?
Genedit has 15 investors. Key investors include Lilly, SK, Korea Investment Holdings, DSC Investment, and KB Investment.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.